Corcept Therapeutics Incorporated (CORT)
Return on total capital
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) (ttm) | US$ in thousands | 136,196 | 142,603 | 127,512 | 120,937 | 105,550 | 96,380 | 97,306 | 99,978 | 112,634 | 126,799 | 131,097 | 131,608 | 124,477 | 118,323 | 106,810 | 110,129 | 128,202 | 132,708 | 140,993 | 130,364 |
| Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 679,589 | 638,835 | 596,243 | 547,864 | 506,705 | 461,679 | 421,614 | 529,584 | 501,842 | 473,364 | 442,326 | 407,811 | 375,806 | 540,229 | 522,675 | 510,802 | 523,338 | 489,680 | 453,698 | 409,489 |
| Return on total capital | 20.04% | 22.32% | 21.39% | 22.07% | 20.83% | 20.88% | 23.08% | 18.88% | 22.44% | 26.79% | 29.64% | 32.27% | 33.12% | 21.90% | 20.44% | 21.56% | 24.50% | 27.10% | 31.08% | 31.84% |
December 31, 2024 calculation
Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $136,196K ÷ ($—K + $679,589K)
= 20.04%
Corcept Therapeutics Incorporated's return on total capital has shown some fluctuations over the periods indicated in the provided data. The return on total capital measures the company's ability to generate profits from the total capital invested in the business.
The return on total capital decreased from 31.84% as of March 31, 2020, to 20.04% as of December 31, 2024, with varying values in between. This downward trend indicates a decreasing efficiency in generating returns relative to the total capital employed.
There have been some periods of improvement, with peaks observed in December 31, 2021 (33.12%) and March 31, 2022 (32.27%). However, these peaks were followed by a general decline in the subsequent quarters.
Overall, the return on total capital for Corcept Therapeutics Incorporated has been on a downward trajectory over the analyzed periods. It suggests that the company may be facing challenges in optimizing its capital investments to generate satisfactory returns for its investors. It would be essential for the company to assess and address the factors contributing to this trend to enhance its financial performance in the future.
Peer comparison
Dec 31, 2024